We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hvivo Plc | LSE:HVO | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.75 | 2.73% | 28.25 | 28.00 | 28.50 | 28.25 | 27.50 | 27.50 | 826,104 | 13:23:49 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 48.48M | -776k | -0.0011 | -256.82 | 190.71M |
Date | Subject | Author | Discuss |
---|---|---|---|
25/1/2023 09:19 | I suspect the new APAC region markets could well prove to be an outlier here with some positive sales occurring this year. | owenski | |
25/1/2023 09:15 | Hardly surprising that its only reached 17p seeing as its short of serious investors. Most folk appear at 8am weekdays. Give it time. Its the old ebidta again - so many businesses scared of pbt. For all we know there’s a load of exceptionals - or not. Guessing game. | yump | |
25/1/2023 09:15 | Finncap retain their 35p target price, and conclude: "Order book and outlook. The orderbook stood at £76m at 31 December 2022, up 65% year-on-year, illustrating the strong delivery by management and increased levels of interest from its pharma/biotech customers in the use of Human Challenge Studies, for which hVIVO remains the undoubted global leader. This excludes the £7.9m of new contract wins in January. With c.95% of FY 2023 revenues already contracted and visibility into 2024, double-digit growth in revenues provides further validation of the long-term sustainable growth model in the human challenge trial market, for which hVIVO is the world leader. - Forecasts and valuation. We have adjusted FY 2022 to reflect the trading update, but leave FY 2023/24 unchanged for the time being. The current price implies the core business is now valued at 2023 EV/Sales and EV/EBITDA of 1.3x and 8.1x, dropping to 1.1x and 6.4x in 2024, respectively. In our view, this neither reflects the estimated underlying growth, the defensive nature of the earnings, nor the strategic value of hVIVO." | rivaldo | |
25/1/2023 09:06 | ZICO, Of course it has! How do you think they managed to get the FY revenue figure after only having £18m at H1, it just shows how many trials they have concluded in the period which is due to the extra capacity, running concurrent trials to increase the through flow. They are allowed to work through the order book, the deposit for a trial is a fraction of the revenue they get when they have concluded the trial. We will get plenty more trials contracted over the next few weeks and months and at much larger sums... | troutisout | |
25/1/2023 09:05 | 17p+is the new cheap level to buy in ..eyeing to hit 20p+sooner..gla | baldrick1 | |
25/1/2023 09:00 | Slow burning process for shorties..on a barbesue..without seasonings.. | baldrick1 | |
25/1/2023 08:46 | Now buyers turn.. easy peasy | baldrick1 | |
25/1/2023 08:44 | Good to see the shorters getting burned yet again eh on HVO! Over the next few days and weeks after the presentations and interviews and number crunching by the fund managers I am confident we will be over 20p especially as a shareholder distribution has been announced for the first time. Growth & Income in a global market leader makes for a great investment long term! | adorling | |
25/1/2023 08:42 | Chica and Sicko, you can now apologise to CF for all those lies and negative stories you have been peddling on here! | legaleagle66 | |
25/1/2023 08:31 | Zico and hamid ,,just buy back before increasing your losses | baldrick1 | |
25/1/2023 08:29 | Overall an excellent trading update but order backlog has decreased which is slightly concerning: From 08/09/2022 "Going forward, I am highly encouraged by the Group's market-leading position, expanding addressable markets, and very substantial order book. With an order book of signed contracts worth c. GBP80m as at 1 September 2022, From today's TU: Strong contracted orderbook of GBP76m, up 65% year-on-year Clearly this has reduced by £4m. | z1co | |
25/1/2023 08:26 | Shares in issue 671 million Or 114 million Mcap at 17p | hamidahamida | |
25/1/2023 08:24 | Let's push the shorties to buy back | baldrick1 | |
25/1/2023 08:24 | I thought we'd open 18p+ I actually got a chunk at 16.8p,so I'm pretty much square now. Glad we have a good CEO now compared to his predecessor. | chica1 | |
25/1/2023 08:23 | Does anyone know how many shares in issue I make it 700 million or so | hamidahamida | |
25/1/2023 08:21 | Let's get back up to 17p+ and upwards | baldrick1 | |
25/1/2023 08:14 | Pausing for the next leg up.. | baldrick1 | |
25/1/2023 08:05 | I deserve to lavish myself for excessive high estimate..50pish..my diligent research on hvo paid off.. | baldrick1 | |
25/1/2023 08:02 | Cracking update | hamidahamida | |
25/1/2023 08:02 | That cash position - 28.4m - well ahead of what I was expecting, and the margins, superb >17% CEO is delivering. | owenski | |
25/1/2023 08:00 | Liberum have raised their target price to 25.1p (from 21.6p).... | rivaldo | |
25/1/2023 08:00 | Lets get shorties up the share price by buying back big time..know who you are.. | baldrick1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions